Results 61 to 70 of about 7,252 (163)
Early Cervical and Orofacial Variable Dystonia in Levodopa‐Naïve PRKN Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Amy Gallagher +6 more
wiley +1 more source
Industrial Psychiatry Journal, 2019 Background: To better understand the psychiatric disorders and cognition in Parkinson's disease (PD) and its impact on quality of life (QoL), patients need to be studied soon after diagnosis, before initiation of dopamine replacement therapy.
Subhendu Shekhar Dhar +4 more
doaj +1 more source
Brain and Behavior, Volume 16, Issue 6, June 2026.In 33 Hakka young‐onset Parkinson's disease (YOPD) patients from western Fujian, whole exome sequencing (WES) plus spinocerebellar ataxia (SCA) panel testing and multiplex ligation‐dependent probe amplification (MLPA) defined the genetic spectrum. Pathological ATXN2 repeat expansion was detected in two cases.
Li‐Ying Pan +5 more
wiley +1 more source
Nonmotor symptoms and sleep disturbances in patients with blepharospasm
Annals of Movement Disorders, 2020 Blepharospasm is a disabling focal dystonia, which is characterized by involuntary bilateral synchronous, excessive blinking and closure of the eyes.
Somdattaa Ray, Pramod K Pal, Ravi Yadav
doaj +1 more source
Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases
MedComm, Volume 7, Issue 6, June 2026.Iron and copper dyshomeostasis, along with their interactions with key intrinsically disordered proteins (e.g., Aβ, tau, α‐synuclein) have a strong implication in the onset and progression of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Prion diseases (PrDs), Huntington's disease (HD), Wilson's disease (WD),
Xin Liu +9 more
wiley +1 more source
Brain and Behavior, Volume 16, Issue 5, May 2026.Schematic summary of visual electrophysiology and retinal and brain pathology. The diagram integrates PVEP abnormalities, retinal pathology, and brain pathology in PFF‐injected mice. Based on behavioral outcomes, the three groups were categorized as control, prodromal PD, and PD, corresponding to the PBS, 3‐month PFF (3 MPI), and 6‐month PFF (6 MPI ...
Qin Zhang +7 more
wiley +1 more source
Movement Disorders Clinical Practice, Volume 13, Issue 5, Page 1124-1146, May 2026.Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma +14 more
wiley +1 more source
Gastrointestinal Dysfunctions Are Associated with IL-10 Variants in Parkinson’s Disease
Parkinson's Disease, 2018 Inflammation has been demonstrated to be involved in Parkinson’s disease (PD) pathogenesis. There were evidences that the disturbance of the protective function of IL-10 gene contributed to PD.
Li Shu +6 more
doaj +1 more source
Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease [PDF]
Parkinson's Disease, 2011 Parkinson disease (PD) is no longer considered a complex motor disorder characterized by Parkinsonism but rather a systemic disease with variegated non-motor deficits and neurological symptoms, including impaired olfaction, autonomic failure, cognitive impairment, and psychiatric symptoms.
openaire +4 more sources
Characteristics of Nonmotor Symptoms in Progressive Supranuclear Palsy
Parkinson's Disease, 2016 Objectives. To explore the clinical correlates of nonmotor symptoms (NMS) in progressive supranuclear palsy (PSP) and their differences from healthy controls and patients with Parkinson’s disease (PD). Methods.
Ruwei Ou +7 more
doaj +1 more source